首页 | 本学科首页   官方微博 | 高级检索  
检索        

那格列奈临床应用中国专家共识
引用本文:宁光,陈璐璐,陈名道,冯凭,高妍,郭晓蕙,李延兵,陆菊明,潘长玉,田浩明,王卫庆,薛耀明,严励,曾龙驿,朱大龙,邹大进.那格列奈临床应用中国专家共识[J].中华内分泌代谢杂志,2011,27(5).
作者姓名:宁光  陈璐璐  陈名道  冯凭  高妍  郭晓蕙  李延兵  陆菊明  潘长玉  田浩明  王卫庆  薛耀明  严励  曾龙驿  朱大龙  邹大进
作者单位:1. 上海市内分泌代谢病临床医学中心,上海市内分泌代谢病研究所,上海交通大学医学院附属瑞金医院内分泌代谢病科,200025
2. 华中科技大学同济医学院附属协和医院内分泌科
3. 天津医科大学总医院内分泌科
4. 北京大学第一医院内分泌科
5. 中山医科大学附属第一医院内分泌科
6. 解放军总医院内分泌科
7. 四川大学华西医院内分泌科
8. 南方医科大学附属南方医院内分泌科
9. 中山大学附属第二医院内分泌科
10. 中山大学附属第三医院
11. 南京大学医学院附属鼓楼医院内分泌科
12. 第二军医大学长海医院内分泌科
摘    要:胰岛素早时相分泌缺陷是导致餐后血糖升高的重要原因.那格列奈是一种速效胰岛素促泌剂,可通过恢复2型糖尿病患者胰岛素早时相分泌以降低餐后血糖.其有效性和安全性得到了充分验证,对2型糖尿病的临床应用也日益广泛.2010年中国2型糖尿病治疗指南将磺脲类与格列奈类统称为胰岛素促泌剂,均作为备选的一线药物.AACE/ACE的共识声明中指出,格列奈类已成为二甲双胍之后的重要选择之一.为了进一步指导那格列奈临床应用,国内16位知名内分泌代谢专家经过认真讨论,拟写了此共识.本共识结合国内外证据,对那格列奈的研究结果进行了系统回顾与总结,对如何临床合理有效应用那格列奈提出指导性建议,供临床医师参考.
Abstract:
Impaired eady phase insulin secretion is an important reason for leading to postprandial hyperglycemia.Nateglinide is a rapid-acting insulin secretagogue,which reduces postprandial blood glucose of type 2diabetic patient by restoring early phase insulin secretion.The efficacy and safety have been fully verified by clinical administration and it is more widely used to treat type 2 diabetic patients.Both sulfonylureas and glinides were named insulin secretagogue agents and regarded as alternative first-line drugs in the 2010 Chinese Guideline for treatment of type 2 diabetes.AACE/ACE Consensus statement claimed that glinides would be one of the important choices after metformin.In order to further guide the clinical application of nateglinide,16 national specialists in the field of endocrinology and metabolism of China discussed,drafted,and edited this consensus.The current consensus combined clinical evidences at home and abroad.systematically reviewed and summarized tlle results of these studies about nateglinide.It will provide guiding recommendations and reference concerning how to reasonably and effectively use nateglinide in the clinical practice.

关 键 词:那格列奈  中国专家共识  糖尿病  2型

Clinical application of nateglinide:a Chinese expert consensus
NING Guang,CHEN Lu-lu,CHEN Ming-dao,FEN Ping,GAO Yan,GUO Xiao-hui,LI Yan-bing,LU Ju-ming,PAN Chang-yu,TIAN Hao-ming,WANG Wei-qing,XUE Yao-ming,YAN Li,ZENG Long-yi,ZHU Da-long,ZOU Da-jin.Clinical application of nateglinide:a Chinese expert consensus[J].Chinese Journal of Endocrinology and Metabolism,2011,27(5).
Authors:NING Guang  CHEN Lu-lu  CHEN Ming-dao  FEN Ping  GAO Yan  GUO Xiao-hui  LI Yan-bing  LU Ju-ming  PAN Chang-yu  TIAN Hao-ming  WANG Wei-qing  XUE Yao-ming  YAN Li  ZENG Long-yi  ZHU Da-long  ZOU Da-jin
Abstract:Impaired eady phase insulin secretion is an important reason for leading to postprandial hyperglycemia.Nateglinide is a rapid-acting insulin secretagogue,which reduces postprandial blood glucose of type 2diabetic patient by restoring early phase insulin secretion.The efficacy and safety have been fully verified by clinical administration and it is more widely used to treat type 2 diabetic patients.Both sulfonylureas and glinides were named insulin secretagogue agents and regarded as alternative first-line drugs in the 2010 Chinese Guideline for treatment of type 2 diabetes.AACE/ACE Consensus statement claimed that glinides would be one of the important choices after metformin.In order to further guide the clinical application of nateglinide,16 national specialists in the field of endocrinology and metabolism of China discussed,drafted,and edited this consensus.The current consensus combined clinical evidences at home and abroad.systematically reviewed and summarized tlle results of these studies about nateglinide.It will provide guiding recommendations and reference concerning how to reasonably and effectively use nateglinide in the clinical practice.
Keywords:Nateglinide  Chinese expert concensus  Diabetes mellitus  type 2
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号